Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 246; no. 2; pp. 534 - 541
• Main Authors: SAN-BAO HWANG, MY-HANH LAM, ALBERTS, A. W, BUGIANESI, R. L, CHABALA, J. C, PONPIPOM, M. M
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Society for Pharmacology and Experimental Therapeutics 01.08.1988
• Subjects: Animals; Binding, Competitive; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Bronchi - drug effects; Bronchi - metabolism; Cell Membrane - drug effects; Cell Membrane - metabolism; Furans - metabolism; Furans - pharmacology; Guinea Pigs; Humans; In Vitro Techniques; Male; man; Medical sciences; Pharmacology. Drug treatments; Platelet Activating Factor - antagonists & inhibitors; Platelet Activating Factor - metabolism; Platelet Aggregation - drug effects; Platelet Membrane Glycoproteins; platelet-activating factor; Rabbits; Receptors, Cell Surface - drug effects; Receptors, Cell Surface - metabolism; Receptors, G-Protein-Coupled; Stereoisomerism; Tritium; Aggregation; In vivo; Bronchoconstriction; Platelet; Antagonist; Respiratory system; In vitro; Biological activity; Platelet activating factor; Biological receptor
• ISSN: 0022-3565; 1521-0103

L-659,989 [trans-2-(3-methoxy-5-methylsulfonyl-4-propoxy-phenyl)-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran] is a p.o. active and extremely potent, selective and competitive platelet-activating factor (PAF) receptor antagonist. It inhibited [3H]PAF binding to either rabbit platelet or rabbit polymorphonuclear leukocyte membranes with an equilibrium inhibition constant (Kl) of 1.1 nM; whereas in human platelet, human polymorphonuclear leukocyte or human lung membranes, L-659,989 was about 10 times less potent with a Kl of 14.3 nM. The structural specificity of L-659,989 was demonstrated by the low activity of its cisisomer which was about 100 to 200 times less potent, also the (-)-L-659,989 was found to be 20- to 30-fold more potent than (+)-L-659,989. In both [3H]PAF binding and PAF-induced platelet aggregation inhibition, L-659,989 was found to be a competitive inhibitor with an equilibrium dissociation constant (KB) of 1.5 and 1.7 nM, respectively, in rabbit platelets. Even up to 6 microM concentration, L-659,989 showed no inhibition on the aggregation of rabbit platelets in plasma induced by ADP, arachidonic acid, collagen or thrombin. In an in vivo model, it inhibited guinea pig bronchoconstriction induced by i.v. infusion of 75 ng/kg of PAF with ED50 values of 13 micrograms/kg i.v. and 0.5 mg/kg p.o.